Status:
COMPLETED
U-LABA/ICS Effects on Exercise Performance, Formoterol
Lead Sponsor:
Morten Hostrup, PhD
Conditions:
Exercise Performance
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current...
Eligibility Criteria
Inclusion
- Age 18-45
- Physically active \>5 hours a week
- Maximum oxygen uptake classified as high or very high
Exclusion
- Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- ECG abnormality
- FEV1/FVC ratio \< 0,7 determined with spirometry
- Chronic illness determined to be a potential risk for participant during the study
- In chronic treatments with medication that may interfere with study results
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Key Trial Info
Start Date :
January 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 4 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06105671
Start Date
January 5 2024
End Date
July 4 2024
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
August Krogh Building
Copenhagen, Denmark, 2100